ClinicalTrials.gg
RecruitingNCT07169734Updated Jul 2, 2026

A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

A Phase 1/2 interventional study of ALE.P03 and ALE.P03 in Cervical Squamous Cell Carcinoma, Squamous Non-small-cell Lung Cancer and Colorectal Cancer, sponsored by Alentis Therapeutics AG. Recruiting at 41 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-02.

Sponsored by Alentis Therapeutics AG · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
180
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 463 studies in Colorectal Neoplasms with a site in Spain — 97 open to participants now, 150 under way, 18 of them phase 3. Colorectal Neoplasms · Spain.

Planned enrollment
195th of 405
180 · median 167
Started
2025
with 33 others
Phase 1/2
67 of 463
21 open now
Primary completion
2029-04
later than 122 of 149 live
Registered
437th of 463
by date

Among the 463 studies in Colorectal Neoplasms with a site in Spain, this one is the 195th largest by planned enrollment of the 405 interventional ones that give a count, is one of 34 that started in 2025, is one of 67 in phase 1/2, reaches primary completion later than 122 of the 149 other live ones, and was the 437th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

97 of the 463 studies in Colorectal Neoplasms with a site in Spain are open now. Recruiting first, the newest first:

92 more — sign in →

All 97 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 463 studies in Colorectal Neoplasms with a site in Spain, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P03 monotherapy in adult patients with selected squamous solid tumors.

Read the detailed description

This Study has a Phase I ALE.P03 monotherapy dose escalation and recommended dose for expansion (RDE) study and a Phase II study of ALE.P03 as monotherapy at RP2D in adult patients with selected advanced or metastatic Claudin-1 positive (CLDN1+) cancers.

03

Conditions studied

  • Cervical Squamous Cell Carcinoma
  • Squamous Non-small-cell Lung Cancer
  • Colorectal Cancer
  • Intrahepatic Cholangiocarcinoma
  • Urothelial Carcinoma

Keywords

  • Claudin-1 Targeted Antibody-Drug Conjugate
  • Monotherapy
  • First-in-Human
  • Recommended Phase 2 dose
  • Recommended dose for expansion
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have histologically and cytologically confirmed advanced or metastatic colorectal cancer, intrahepatic cholangiocarcinoma, squamous non-small cell lung cancer, urothelial carcinoma, and cervical squamous cell carcinoma.
  • Have documented radiological disease progression at study entry.
  • Have provided tissue for CLDN1 (Claudin-1) analysis in a central laboratory.

Phase I Dose Escalation:

- Received and being /intolerant to available systemic standard of care (SOC) regimens (based on local institutional guidelines) for advanced disease.

Phase I RDE and Phase II:

  • Received 1-2 available systemic SOC regimens (based on local institutional guidelines) for advanced disease and being refractory or intolerant to treatment.
  • Patients with actionable oncogenic drivers: received feasible targeted therapy.

Applicable for Phase I Dose Escalation, Phase I RDE and Phase II:

  • per 1.1, as determined by the site.
  • Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Groups Performance Status.
  • Demonstrate adequate bone marrow and organ function as per the protocol.

Exclusion criteria

Exclusion Criteria:

  • SqNSCLC and CSCC: diagnosed with a tumor of predominantly non-squamous histology result or adenocarcinoma.
  • Has received antineoplastic therapies prior to study intervention within specified time frame.
  • Has rapidly progressing disease.
  • Has known active central nervous system and/or carcinomatous meningitis.
  • Has a history of (non-infectious) interstitial lung disease/pneumonitis that required or current symptomatic or pneumonitis requiring steroids and/or therapies.
  • Has clinically significant gastrointestinal bleeding.
  • Has an active infection requiring systemic treatment.
  • Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the clinical study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Phase I Dose Escalation- ALE.P03

    Patients will receive ALE.P03 as monotherapy via intravenous infusion. The ALE.P03 will be given at an escalated dose until Maximum tolerated dose (MTD) and/or a safe recommended dose for expansion (RDE) is determined in Phase I dose escalation part of the study.

    Drug: ALE.P03

  • Experimental
    Phase I Dose Expansion- ALE.P03

    Patients will receive ALE.P03 as monotherapy via intravenous infusion. The safe recommended doses of ALE.P03 will be given in Phase I dose expansion part of the study to identify recommended Phase II dose (RP2D) for Phase II.

    Drug: ALE.P03

  • Experimental
    Phase II- ALE.P03

    Patients will receive ALE.P03 as monotherapy via intravenous infusion at the RP2D, or according to the dosing schedule after the dose expansion phase.

    Drug: ALE.P03

Interventions

  • DrugALE.P03

    ALE.P03, will be administered by IV infusion according to the assigned arms.

  • DrugALE.P03

    ALE.P03, will be administered by IV infusion according to the assigned arms.

  • DrugALE.P03

    ALE.P03, will be administered by IV infusion according to the assigned arms.

06

What researchers measure

Primary outcomes

  1. Number of Patients with Dose Limiting Toxicities (DLTs) (Phase I)

    DLTs as defined in the protocol will be assessed to evaluate safety and tolerability of ALE.P03 (Phase I Dose Escalation), and to establish RP2D for ALE.P03 (Phase I RDE).

    Time frame: Up to 28 days

  2. Number of Patients with Adverse Events (Phase I)

    Adverse events will be assessed to evaluate safety and tolerability of ALE.P03 (Phase I Dose Escalation), and to establish RP2D for ALE.P03 (Phase I RDE).

    Time frame: From Day 1 up to Safety follow-up (30 ± 5 days post last dose [Up to 4 years])

  3. Overall Response Rate (ORR) (Phase I)

    The ORR is the proportion of patients with a best overall response (BOR) of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1.) This is assessed to establish RP2D for ALE.P03 (Phase I RDE)

    Time frame: From ALE.P03 treatment initiation until at or prior to initiation of the use of new anti-cancer therapy (Up to 4 years)

  4. Duration of Response (DoR) (Phase I)

    The DoR is defined for patients achieving a CR or PR as per Investigator review according to RECIST 1.1 to disease progression before new anti-cancer therapy or death of any cause, whichever occurs earlier. This is assessed to establish RP2D for ALE.P03 (Phase I RDE).

    Time frame: From ALE.P03 treatment initiation until disease progression or study completion (Up to 4 years)

  5. Overall Response Rate (ORR) (Phase II)

    The ORR is assessed to assess anti-tumor activity of ALE.P03 (Phase II).

    Time frame: From ALE.P03 treatment initiation until at or prior to initiation of the use of new anti-cancer therapy (Up to 4 years)

  6. Duration of Response (DoR) (Phase II)

    The DoR is defined for patients achieving a confirmed CR or PR as the time from the initial response of CR or PR to disease progression before new anti-cancer therapy or death of any cause, whichever occurs earlier. This is assessed to assess anti-tumor activity of ALE.P03 (Phase II).

    Time frame: From ALE.P03 treatment initiation until disease progression or study completion (Up to 4 years)

Secondary outcomes

  1. Number of Patients with Adverse Events (Phase I RDE and Phase II)

    Adverse events will be assessed to evaluate safety and tolerability of ALE.P03 (Phase I RDE and Phase II)

    Time frame: From Day 1 up to Safety follow-up (30 ± 5 days post last dose [Up to 4 years]

  2. Disease control rate (DCR) (Phase I and II)

    The DCR is defined as the proportion of patients with a BOR of CR or PR or stable disease (SD) per Investigator review according to RECIST 1.1 at or prior to initiation of the use of new anti-cancer therapy. This is assessed to evaluate preliminary evidence of anti-tumor activity of ALE.P03 (Phase I and II).

    Time frame: From ALE.P03 treatment initiation until at or prior to initiation of the use of new anti-cancer therapy (Up to 4 years)

  3. Median Progression-Free Survival (PFS) rate at 6 and 12 Months (Phase I and II)

    The PFS is defined as time from first study treatment to a documented disease progression according to RECIST 1.1, as determined by the Investigator, or death due to any cause, whichever occurs earlier. This is assessed to evaluate preliminary evidence of anti-tumor activity of ALE.P03 (Phase I and II).

    Time frame: At 6 and 12 months after initiation of ALE.P03 treatment

  4. Median Overall Survival (OS) rate at 6, 12, and 24 Months (Phase I and II)

    The OS is defined as time from first study treatment to death due to any cause. This is assessed to evaluate preliminary evidence of anti-tumor activity of ALE.P03 (Phase I and II).

    Time frame: At 6, 12, and 24 months after initiation of ALE.P03 treatment

  5. Blood Concentration of ALE.P03 Antibody-drug Conjugate (ADC) (Phase I and II)

    Concentrations of ALE.P03 ADC in blood will be measured at each scheduled time point per arms.

    Time frame: Phase I and II: From Day 1 until at end of treatment visit (EoT) (Up to 4 years)

  6. Blood Concentrations of Total Antibody (Phase I and II)

    Concentrations of total antibody in blood will be measured at each scheduled time point per arms.

    Time frame: Phase I and II: From Day 1 until at EoT (Up to 4 years)

  7. Blood Concentrations of Payload (Phase I and II)

    Concentrations of payload in blood will be measured at each scheduled time point per arms.

    Time frame: Phase I and II: From Day 1 until at EoT (Up to 4 years)

  8. Area under the concentration-time curve over the dosing interval (AUCtau) (Phase I and II)

    The AUCtau of ALE.P03 will be measured to assess the pharmacokinetic (PK) profile of ALE.P03.

    Time frame: Phase I and II: From Day 1 until at EoT (Up to 4 years)

  9. Area under the concentration-time curve from pre-dose (time 0) to the time of the last quantifiable concentration (AUClast) (Phase I and II)

    The AUClast of ALE.P03 will be measured to assess the PK profile of ALE.P03.

    Time frame: Phase I and II: From Day 1 until at EoT (Up to 4 years)

  10. Area under the concentration-time curve from pre-dose (time 0) extrapolated to infinite time (AUCinf) (Phase I and II)

    The AUCinf of ALE.P03 will be measured to assess the PK profile of ALE.P03.

    Time frame: Phase I and II: From Day 1 until at EoT (Up to 4 years)

  11. Maximum Concentration (Cmax) (Phase I and II)

    The Cmax of ALE.P03 will be measured to assess the PK profile of ALE.P03. It is determined directly from the concentration-time profile.

    Time frame: Phase I and II: From Day 1 until at EoT (Up to 4 years)

  12. Minimum concentration (Cmin) (Phase I and II)

    The Cmin of ALE.P03 will be measured to assess the PK profile of ALE.P03. It is determined directly from the concentration-time profile.

    Time frame: Phase I and II: From Day 1 until at EoT (Up to 4 years)

  13. Concentration at the end of a dosing interval (Ctrough) (Phase I and II)

    The Ctrough of ALE.P03 will be measured to assess the PK profile of ALE.P03.

    Time frame: Phase I and II: From Day 1 until at EoT (Up to 4 years)

  14. The terminal elimination rate constant (KeL) (Phase I and II)

    The KeL of ALE.P03 will be measured to assess the PK profile of ALE.P03. It is determined by selection of at least three data points on the terminal phase of the concentration-time curve.

    Time frame: Phase I and II: From Day 1 until at EoT (Up to 4 years)

  15. Terminal elimination half-life (t½) (Phase I and II)

    The t½ of ALE.P03 will be measured to assess the PK profile of ALE.P03.

    Time frame: Phase I and II: From Day 1 until at EoT (Up to 4 years)

  16. Time of Maximum Concentration (tmax) (Phase I and II)

    The tmax of ALE.P03 will be measured to assess the PK profile of ALE.P03. It is determined directly from the concentration-time profile.

    Time frame: Phase I and II: From Day 1 until at EoT (Up to 4 years)

  17. Average Concentration (Cavg) (Phase I and II)

    The Cavg of ALE.P03 will be measured to assess the PK profile of ALE.P03.

    Time frame: Phase I and II: From Day 1 until at EoT (Up to 4 years)

  18. Number of Patients with Presence of anti-ALE.P03 Antibodies (Phase I and II)

    Presence of anti-ALE.P03 Antibodies will be assessed to evaluate the immunogenicity of ALE.P03.

    Time frame: Phase I and II: From Day 1 until at EoT (Up to 4 years)

  19. Number of Patients with Positive anti-ALE.P03 Antibodies (Phase I and II)

    Presence of anti-ALE.P03 Antibodies (positive/negative) will be assessed to evaluate the immunogenicity of ALE.P03.

    Time frame: Phase I and II: From Day 1 until at EoT (Up to 4 years)

07

Study locations

41 of 41 sites recruiting
  • Mayo Clinic Comprehensive Cancer Center
    Phoenix, Arizona 85054, United States
    Recruiting
    • Principal Investigator · Contact
  • USC Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
    Recruiting
    • Principal Investigator · Contact
  • Yale Comprehensive Cancer Center
    New Haven, Connecticut 06510, United States
    Recruiting
    • Principal Investigator · Contact
  • The University of Chicago Medical Center - Oncology
    Chicago, Illinois 60637, United States
    Recruiting
    • Principal Investigator · Contact
    • Principal Investigator · Principal investigator
  • Norton Cancer Institute - Norton Healthcare Pavilion
    Louisville, Kentucky 40202, United States
    Recruiting
    • Principal Investigator · Contact
  • John Theurer Cancer Center
    Hackensack, New Jersey 07601, United States
    Recruiting
    • Principal Investigator · Contact
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
    Recruiting
    • Principal Investigator · Contact
  • Next Oncology-Oncology
    San Antonio, Texas 78229, United States
    Recruiting
    • Principal Investigator · Contact
  • NEXT Oncology Virginia
    Fairfax, Virginia 22031, United States
    Recruiting
    • Principal Investigator · Contact
  • Centre Georges Francois Leclerc - Oncologie Medicale
    Dijon, 21000, France
    Recruiting
    • Principal Investigator · Contact
    • Principal Investigator · Principal investigator
  • CHU La Timone
    Marseille, 13005, France
    Recruiting
    • Principal Investigator · Contact
    • Principal Investigator · Principal investigator
  • Centre Hospitalier Universitaire (CHU) de Toulouse - Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-Oncopole)
    Toulouse, 31100, France
    Recruiting
    • Principal Investigator · Contact
    • Principal Investigator · Principal investigator
  • Institut Gustave Roussy (IGR)
    Villejuif, 94800, France
    Recruiting
    • Principal Investigator · Contact
  • Prince of Wales Hospital (PWH) - The Chinese University of Hong Kong (CUHK)
    Hong Kong, Hong-Kong, Hong Kong
    Recruiting
    • Principal Investigator · Contact
  • Oncologo presso Ospedale ASST Grande Ospedale Metropolitano Niguarda
    Milan, 20162, Italy
    Recruiting
    • Principal Investigator · Contact
    • Principal Investigator · Principal investigator
  • Ospedale San Raffaele, IRCCS - Oncologia Medica
    Milan, 20132, Italy
    Recruiting
    • Principal Investigator · Contact
  • Fondazione IRCCS Istituto Nazionale dei Tumori
    Milan, 20133, Italy
    Recruiting
    • Principal Investigator · Contact
  • IEO - Istituto Europeo di Oncologia, IRCCS
    Milan, 20141, Italy
    Recruiting
    • Principal Investigator · Contact
  • Ravenna - Ospedale S. Maria delle Croci
    Ravenna, 48121, Italy
    Recruiting
    • Principal Investigator · Contact
    • Principal Investigator · Principal investigator
  • IRCCS Istituto Clinico Humanitas di Rozzano
    Rossano, 20089, Italy
    Recruiting
    • Principal Investigator · Contact
    • Principal Investigator · Principal investigator
  • Policlinico Santa Maria alle Scotte, Azienda Ospedaliero Universitaria Senese - Immunoterapia Oncologica
    Siena, 53100, Italy
    Recruiting
    • Principal Investigator · Contact
    • Principal Investigator · Principal investigator
  • The Netherlands Cancer Institute (NKI)
    Amsterdam, 1066, Netherlands
    Recruiting
    • Principal Investigator · Contact
    • Principal Investigator · Principal investigator
  • Radboudumc - Centrum voor Oncologie
    Nijmegen, 6525, Netherlands
    Recruiting
    • Principal Investigator · Contact
  • Erasmus University Medical Center
    Rotterdam, 3015, Netherlands
    Recruiting
    • Principal Investigator · Contact
    • Principal Investigator · Principal investigator
  • National University Hospital (NUH) - Medical Oncology
    Singapore, 119074, Singapore
    Recruiting
    • Principal Investigator · Contact
  • National Cancer Centre Singapore (NCCS)
    Singapore, 168583, Singapore
    Recruiting
    • Principal Investigator · Contact
  • Hospital HM Nou Delfos
    Barcelona, 08023, Spain
    Recruiting
    • Principal Investigator · Contact
  • Vall d'Hebron University Hospital
    Barcelona, 08035, Spain
    Recruiting
    • Principal Investigator · Contact
  • See outside Hospital Universitario Reina Sofia
    Córdoba, 14004, Spain
    Recruiting
    • Principal Investigator · Contact
  • Virgen of Arrixaca University Clinical Hospital
    El Palmar, 30120, Spain
    Recruiting
    • Principal Investigator · Contact
  • Ramón y Cajal Hospital
    Madrid, 28034, Spain
    Recruiting
    • Principal Investigator · Contact
  • Hospital Universitario Fundación Jiménez Díaz
    Madrid, 28040, Spain
    Recruiting
    • Principal Investigator · Contact
  • HM Sanchinarro University Hospital
    Madrid, 28050, Spain
    Recruiting
    • Principal Investigator · Contact
  • University Hospital Quironsalud Madrid
    Madrid, 28223, Spain
    Recruiting
    • Principal Investigator · Contact
  • Hospital universitario virgen macarena
    Seville, 41009, Spain
    Recruiting
    • Principal Investigator · Contact
  • San Juan de Reus University Hospital
    Tarragona, 43204, Spain
    Recruiting
    • Principal Investigator · Contact
  • Hospital Clinico Universitario de Valencia
    Valencia, 46010, Spain
    Recruiting
    • Principal Investigator · Contact
  • La Fe University and Polytechnic Hospital
    Valencia, 46026, Spain
    Recruiting
    • Principal Investigator · Contact
  • National Cheng Kung University Hospital
    Tainan, 100225, Taiwan
    Recruiting
    • Principal Investigator · Contact
    • Principal Investigator · Principal investigator
  • National Taiwan University Hospital
    Taipei, 100225, Taiwan
    Recruiting
    • Principal Investigator · Contact
    • Principal Investigator · Principal investigator
  • Chang Gung Medical Foundation - LinKou Chang Gung Memorial Hospital - Oncology
    Taoyuan, 33305, Taiwan
    Recruiting
    • Principal Investigator · Contact
    • Principal Investigator · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Apr 2029, 43 months after the start.

Of 159 industry-sponsored phase 1/2 interventional studies under Colorectal Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 82. This study's planned 43 months is below that.

Counting every sponsor, half of 261 studies reached it within 59 months; a quarter within 36 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2025
First posted
Sep 12, 2025
StartActual
Aug 26, 2025
Primary completionEst.
Apr 5, 2029
CompletionEst.
Oct 4, 2029
Last update
Jul 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07169734
Lead sponsor
Alentis Therapeutics AG
Responsible party
Sponsor
First posted
Sep 12, 2025
Start date
Aug 26, 2025
Primary completion
Apr 5, 2029 (estimated)
Completion
Oct 4, 2029 (estimated)
Last update
Jul 2, 2026

Study contacts

Alentis Clinical Trial Contact
Contact
patientinfo@alentis.ch
+41782304288

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion